Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis
By Elana Gotkine HealthDay Reporter
FRIDAY, May 2, 2025 -- For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study published online April 30 in the New England Journal of Medicine.
Arun J. Sanyal, M.D., from the Virginia Commonwealth University School of Medicine in Richmond, and colleagues conducted a multicenter, randomized, placebo-controlled trial involving 1,197 patients with biopsy-defined MASH and fibrosis stage 2 or 3. Participants were randomly assigned to receive once-weekly subcutaneous semaglutide 2.4 mg or placebo for 240 weeks (534 and 266 patients, respectively). The primary end points of resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis were assessed at a planned interim analysis conducted at 72 weeks.
The researchers found that resolution of steatohepatitis without worsening of fibrosis occurred in 62.9 and 34.3 percent of patients in the semaglutide and placebo groups, respectively. A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8 and 22.4 percent of those in the semaglutide and placebo groups, respectively. Secondary outcomes included combined resolution of steatohepatitis and reduction in liver fibrosis, which was reported in 32.7 and 16.1 percent of those in the semaglutide and placebo groups, respectively, and mean change in body weight of −10.5 and −2.0 percent with semaglutide and placebo, respectively.
"In the current ongoing phase 3 trial, we found evidence for the superiority of semaglutide over placebo for histologic reductions in steatohepatitis and fibrosis," the authors write.
The study was funded by Novo Nordisk, the manufacturer of semaglutide.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
DDW: Certain Proteins Predict Metabolic Dysfunction-Associated Steatotic Liver Disease
FRIDAY, April 25, 2025 -- Five proteins are significant predictors of metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study presented at the 2025...
AI Algorithm Can ID Metabolic Dysfunction-Associated Steatotic Liver Disease
WEDNESDAY, Nov. 27, 2024 -- An algorithm can identify individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) with about 88 percent accuracy using...
GLP-1 RA Use Linked to Reduced Cirrhosis Risk in MASLD, Diabetes
TUESDAY, Sept. 17, 2024 -- For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.